Organogenesis Holdings Inc. (ORGO)
ORGO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1661181/000119312526076730/0001193125-26-076730-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ORGO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001661181 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $564.2M |
| Net income | $37.0M |
| Operating income | $44.7M |
| Net margin | 6.6% |
| Operating margin | 7.9% |
| Revenue growth | +17.0% |
| Cash | $93.7M |
| Total assets | $598.7M |
| P/E (computed) | 2.8× |
| P/S (computed) | 0.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $21.3M cash; operating cash flow $2.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 129,801,720 (2026-10-30); 126,912,142 a year earlier; 132,041,164 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | RSM US LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $40K, sold $2.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $45.5M | -$29.6M | -$18.6M | $21.3M | No debt tags | $352.0M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $43.8M | -$96.3M | -$31.7M | $46.1M | No debt tags | $457.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $37.2M | -$53.2M | $21.1M | $91.4M | No debt tags | $514.7M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $225.6M | $43.7M | $39.4M | $93.7M | No debt tags | $564.2M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $150.9M | $21.6M | $3.1M | $63.7M | No debt tags | $465.2M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $101.0M | -$9.4M | -$32.9M | $73.1M | No debt tags | $429.5M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $86.7M | -$18.8M | -$19.9M | $110.0M | No debt tags | $458.8M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $126.7M | $7.7M | $10.9M | $135.6M | No debt tags | $482.0M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-06 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 673 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.4% |
| 1 month | -33.1% |
| 3 months | -54.0% |
| Year to date | -84.4% |
| 1 year | -87.0% |
| From 52-week high | -86.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DERM | Journey Medical Corporation | $3.70 | -14.55% | $104.5M |
| CLLS | Cellectis S.A. | $1.04 | -11.86% | $104.5M |
| UNCY | Unicycive Therapeutics Inc. | $3.70 | +4.23% | $103.1M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| CUE | Cue Biopharma Inc. | $14.10 | -12.53% | $102.4M |
| OGI | Organigram Global Inc. Common Shares | $0.7240 | -12.62% | $102.2M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier